The US Food and Drug Administration (FDA) is prioritizing the development and review of new therapies to treat COVID-19 through a recently created special emergency program titled Coronavirus Treatment Acceleration Program...more
4/10/2020
/ Applicable Manufacturers ,
Biologics ,
Breakthrough Therapy Designation ,
Coronavirus Treatment Acceleration Program (CTAP) ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Intellectual Property Protection ,
Life Sciences ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs
Recognizing the disruptions caused by COVID-19, the United States Patent and Trademark Office (“USPTO”) is providing fee waivers for certain applicants that cannot meet filing deadlines to maintain their intellectual property...more
The coronavirus pandemic is affecting nearly all aspects of life around the globe. Recognizing the disruptive nature resulting from the spread of the virus and containment efforts, the United States Patent and Trademark...more
Seyfarth hosted its first “Future of Cosmetics and Personal Care Products" event in its New York office on November 12, 2019. The event brought together industry leaders and Seyfarth attorneys for a timely conversation on the...more
11/26/2019
/ Amazon Marketplace ,
Brand ,
Cannabidiol (CBD) oil ,
Cannabis Products ,
Consumer Review Fairness Act (CRFA) ,
Corporate Branding ,
Cosmetics ,
Endorsements ,
Food and Drug Administration (FDA) ,
FTC Endorsement Guidelines ,
Funding Options ,
Influencers ,
Intellectual Property Protection ,
Litigation Fees & Costs ,
Marijuana ,
Marketing ,
Marketing Perspectives ,
Natural Products ,
Patent Infringement ,
Patents ,
Personal Care Products ,
Risk Management ,
USPTO
The Hatch-Waxman Act was enacted in 1984 to address two main congressional goals: (1) to encourage innovation in pharmaceutical research and development; and (2) to help generic drugs reach the market more quickly. Through...more
3/16/2018
/ Abbreviated New Drug Application (ANDA) ,
Biologics ,
Biosimilars ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Hatch-Waxman ,
Intellectual Property Protection ,
Life Sciences ,
Patent Infringement ,
Patent Litigation ,
Patent-in-Suit ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs
Seyfarth Synopsis: In its first opinion relating to the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), the Supreme Court in Sandoz Inc. v. Amgen Inc. provided a win to biosimilar companies, eliminating the...more
Seyfarth Synopsis: Venue in a patent litigation is limited to the alleged infringer’s state of incorporation or where the defendant has committed infringing acts and has a regular and established place of business....more
6/6/2017
/ Food Manufacturers ,
Forum Shopping ,
Intellectual Property Protection ,
Multidistrict Litigation ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Personal Jurisdiction ,
SCOTUS ,
State of Incorporation ,
TC Heartland LLC v Kraft Foods ,
Venue